This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol. 2003;170:5–11. EBM III. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db =PubMed&list_uids=12796635&dopt=Abstract.
McGlynn KA, Devesa SS, Sigurdson AJ, Brown LM, Tsao L, Tarone RE. Trends in the incidence of testicular germ cell tumors in the United States. Cancer. 2003;97:63–70. EBM III–IIb.
Dieckmann KP, Loy V. Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasm. J Clin Oncol. 1996;14:3126–32. EBM IIa–IIb.
Moller H, Prener A, Skakkebaek NE. Testicular cancer, cryptorchidism, inguinal hernia, testicular atrophy and genital malformations: case-control studies in Denmark. Cancer Causes Control. 1996;7:264–74. EBM IIa. http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db=PubMed&liuids=8740739 & dopt=Abstract.
International Germ Cell Cancer Collaborative Group (IGCCCG). The International Germ Cell Consensus Classification: a prognostic factor based staging system for metastatic germ cell cancer. J Clin Oncol. 1997;15:594–603. EBM IA/IIA/IIB/III.
Leibovitch I, Foster RS, Kopecky KK, et al. Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: A combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment. J Clin Oncol. 1998;16:261–8.
White PM, Howard GC, Best JJ, et al. The role of computed tomographic examination of the pelvis in the management of testicular germ cell tumours. Clin Radiol. 1997;52:124–9. EBM IIB.
White PM, Adamson DJA, Howard GCW, et al. Imaging of the thorax in the management of germ cell testicular tumours. Clin Radiol. 1999;54:207–11. EBM IIB+III.
Meyer CA, Conces DJ. Imaging of intrathoracic metastases of nonseminomatous germ cell tumors. Chest Surg Clin N Am. 2002;12:717–38.
See WA, Hoxie L. Chest staging in testis cancer patients: imaging modality selection based upon risk assessment as determined by abdominal computerized tomography scan results. J Urol. 1993;150:874–8.
Leibovitch I, Foster RS, Kopecky KK, et al. Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell tumor using size criteria of retroperitoneal lymph nodes. J Urol. 1995;154:1759–63.
Bellin M, Roy C, Kinkel K, Thoumas D, et al. Lymph node metastases: Safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles - initial clinical experience. Radiology. 1998;207:799–808.
Hogeboom WR, Hoekstra HJ, Mooyart EL, et al. Magnetic resonance imaging of retroperitoneal lymph node metastases of non-seminomatous germ cell tumors of the testis. Eur J Surg Oncol. 1993;19:429–37.
Albers P, Bender H, Yilmaz H, et al. Positron emission tomography in the clinical staging of patients with stage I and II germ cell tumors. Urology. 1999;53:808–11. EBM III.
Cremerius U, Wildberger JE, Borchers H, et al. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? - Results of a study of 50 patients. Urology. 1999;54:900–4.
Hoh CK, Seltzer MA, Franklin J, et al. Positron emissions tomography in urological oncology. J Urol. 1998;159:347–56.
Weber WA, Avril N, Schwaiger M. Relevance of positron emission tomography (PET) in oncology. Strahlenther Onkol. 1999;175:356–76.
Tsatalpas P, Beuthien-Baumann B, Kropp J, Manseck A, Tiepolt C, Hakenberg OW, et al. Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors. Urol Int. 2002;68:157–63.
Spermon JR, De Geus-Oei LF, Kiemeney LA, Witjes JA, Oyen WJ. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int. 2002;89:549–56.
De Wit M for the German Testicular Cancer Study Group. 18-FDG PET staging in early stage testicular cancer. Proceedings ASCO 2005, abstract no 4504.
De Santis M, Bokemeyer C, Becherer A, Stoiber F, Oechsle K, Kletter K, et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol. 2001;19:3740–44. EBM IIb. http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11533096&do-pt=Abstract.
De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective mulitcentric SEMPET trial. J Clin Oncol. 2004; 22:1034–9.EBM IIb.
Becherer A, Santis MD, Karanikas G, Szabo M, Bokemeyer C, Dohmen BM, et al. FDG PET is superior to CT in the prediction of viable tumour in post–chemotherapy seminoma residuals. Eur J Radiol. 2005;54:284–8. EBM IIb.
Bokemeyer C, Nowak P, Haupt A, et al. Treatment of brain metastases in patients with testicular cancer. J Clin Oncol. 1997;15:1449–54. EBM III.
Fossa SD, Bokemeyer C, Gerl A, et al. Treatment outcome of patients with brain metastases from malignant germ cell tumors. Cancer. 1999;85:988–997. EBM IIA.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag London Limited
About this chapter
Cite this chapter
Albers, P., Laguna, P. (2009). Testicular Carcinoma: Introduction. In: de la Rosette, J.J., Manyak, M.J., Harisinghani, M.G., Wijkstra, H. (eds) Imaging in Oncological Urology. Springer, London. https://doi.org/10.1007/978-1-84628-759-6_25
Download citation
DOI: https://doi.org/10.1007/978-1-84628-759-6_25
Publisher Name: Springer, London
Print ISBN: 978-1-84628-514-1
Online ISBN: 978-1-84628-759-6
eBook Packages: MedicineMedicine (R0)